Facebook Linkedin RSS Twitter Youtube
Home 2024

Tessera Therapeutics

Prime Medicine Spat with Tessera Rumbles on at ESGCT
Genome Editing

Prime Medicine Spat with Tessera Rumbles on at ESGCT

Top Five Privately Held Gene Editing Therapy Companies
A-Lists

Top Five Privately Held Gene Editing Therapy Companies

ASGCT 2024: David Liu Touts Rapid Evolution of Gene-Sized Programmable Editing Technologies
Genome Editing

ASGCT 2024: David Liu Touts Rapid Evolution of Gene-Sized Programmable Editing Technologies

Gene Writing and Rewriting: The Key to Unlocking its Full Potential
Drug Discovery

Gene Writing and Rewriting: The Key to Unlocking its Full Potential

PASTE, Don’t Cut: Genome Editing Tool Looks Beyond CRISPR and Prime
Genome Editing

PASTE, Don’t Cut: Genome Editing Tool Looks Beyond CRISPR and Prime

Biotech Leaders Discuss Therapeutic Breakthroughs at the WuXi AppTec Global Forum
Artificial Intelligence

Biotech Leaders Discuss Therapeutic Breakthroughs at the WuXi AppTec Global Forum

Nucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure Diseases
GEN Edge

Nucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure Diseases

Novel Gene Editing Systems Come Into Their Own
Genome Editing

Novel Gene Editing Systems Come Into Their Own

Tessera Rewrites the Genome Script Using Mobile Genetic Elements
GEN Edge

Tessera Rewrites the Genome Script Using Mobile Genetic Elements

Affymetrix and Tessarae to Develop Tests for Public Health and Biodefense Surveillance
News

Affymetrix and Tessarae to Develop Tests for Public Health and Biodefense Surveillance

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.